Skip to content
Operation Infinite Justice – Lifestyle
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
August 28, 2026
Kazia Therapeutics Limited Announces Proposed Public Offering
August 28, 2026
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
July 28, 2026
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026
←
Previous Page
1
2